<DOC>
	<DOCNO>NCT00499720</DOCNO>
	<brief_summary>The primary objective program provide expand access aztreonam lysine inhalation ( AZLI ) 75 mg prior commercial availability patient cystic fibrosis ( CF ) chronic P. aeruginosa airway infection limit treatment option risk disease progression .</brief_summary>
	<brief_title>Aztreonam Lysine Inhalation Patients With Cystic Fibrosis Pseudomonas Aeruginosa Airway Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible participation study : ≥ 6 year age Subject CF diagnose one following : Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test Two well characterize genetic mutation CFTR gene Abnormal nasal potential difference accompany symptom characteristic CF At high risk disease progression define one follow subject population : First Cohort Criteria : Those wait list eligible lung transplant base FEV1 criterion . Patients level lung function impairment consistent lung transplantation criterion , ineligible transplantation reason , enroll program ; Completed participation CPAI006 ( Visit 20 ) . Subjects withdraw CPAI006 prior complete course AZLI study visit eligible protocol . Second Cohort Criteria : Meets first cohort criterion FEV1 ≤ 40 % predicted time consent Third Cohort Criteria : Meets first second cohort criterion FEV1 ≤ 50 % predicted time consent Subjects meet follow exclusion criterion enrol study : Subjects serious active medical psychiatric illness , opinion investigator , would interfere subject treatment , assessment compliance protocol dosing requirement Subjects hypersensitivity component drug product Currently enrol another clinical trial Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>airway infection</keyword>
	<keyword>Aztreonam Lysine Inhalation</keyword>
</DOC>